Germany agrees deal with CureVac, GSK for mRNA vaccines until 2029
The five-year contract allows for production of up to 80 million doses at short notice until 2029, CureVac said, adding that those…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
CureVac
Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrates improved immune response and…
Pre-clinical study provides evidence for improved immune responses with second-generation mRNA backbone jointly developed by…
Bayer examining if it can help CureVac with COVID-19 vaccine production: CEO
CureVac's COVID-19 vaccine candidate is in late-stage clinical trials and has not yet been approved
CureVac expects to produce COVID-19 vaccine at scale by year-end
It is one of a number of firms developing vaccines based on molecules carrying a genetic code called messenger RNA (mRNA) to treat…
EU, CureVac may sign deal for 225 million doses of COVID-19 vaccine
CureVac said it could start large-scale human trials on its vaccine in the last quarter of this year based on results of its…
CureVac nets EU funding to ramp up vaccine production
CureVac, backed by the Bill & Melinda Gates Foundation, is a pioneer in the so-called messenger RNA approach, which is also…